Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 0% | < 30% | Pass |
| Interest-bearing investments / market cap | 20.44% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0% of any dividend from NATCOPHARM should be given to charity. Calculate your amount →
A steep one-month drop, negative 3–6 month returns, and a near 30% drawdown despite the 50-day above the 200-day point to a prior uptrend under pressure or in transition. Sector sentiment is not highlighted, so there is no clear external offset to this weakness.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.